Response to Crizotinib After Entrectinib Resistance in <i>ROS1</i> -Rearranged, <i>MET</i> -Amplified Lung Adenocarcinoma

Authors

Institutions

Publication Details

Journal
JCO Precision Oncology
Published
2024-10-01
DOI
https://doi.org/10.1200/po-24-00394
Citations
1
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Response to Crizotinib After Entrectinib Resistance in ROS1 -Rearranged, MET -Amplified Lung Adenocarcinoma

Arushi Gahlot Saini, Adriana Barrichello, Federica Pecci, Biagio Ricciuti et al.
1 citations
JCO Precision Oncology
Lung Cancer Treatments and Mutations
0.42
article

Response to Crizotinib After Entrectinib Resistance in ROS1 -Rearranged, MET -Amplified Lung Adenocarcinoma

Arushi Gahlot Saini, Adriana Barrichello, Federica Pecci, Biagio Ricciuti, Victor R. Vaz, Arielle Elkrief, Marc Ladanyi, Jacob M. Sands, Mihaela D. Aldea, Malini Gandhi, Joao V. Alessi, Mark M. Awad, Chad Vanderbilt, Lynette M. Sholl
article en
1 citations

Abstract

No abstract available for this paper.
JCO Precision OncologyVol. 8(8)
Brigham and Women's Hospital (US), Memorial Sloan Kettering Cancer Center (US), Harvard University (US), Dana-Farber Cancer Institute (US)
Good health and well-being
Openalex Percentile: Top 32%
Lung Cancer Treatments and Mutations
0.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.